Unicycive Therapeutics annual return on equity
2021
2022
2024
2025
Unicycive Therapeutics Return on Equity (ROE) Growth & History (UNCY)
Unicycive Therapeutics's return on equity was −141.14% for fiscal 2025.
View full Unicycive Therapeutics company overviewUnicycive Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −141.14% | +1886.96 pp |
| 2024 | 2024-12-31 | −2,028.11% | — |
| 2022 | 2022-12-31 | −225.47% | −80.43 pp |
| 2021 | 2021-12-31 | −145.04% | — |
Unicycive Therapeutics quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −3.79% | +42.76 pp |
| Q1 2026 | 2026-03-31 | −37.77% | −43.87 pp |
| Q4 2025 | 2025-12-31 | −43.34% | — |
| Q3 2025 | 2025-09-30 | −22.30% | — |
| Q2 2025 | 2025-06-30 | −46.55% | — |
| Q1 2025 | 2025-03-31 | 6.10% | — |
| Q4 2022 | 2022-12-31 | −256.15% | −240.64 pp |
| Q3 2022 | 2022-09-30 | −76.46% | −6.15 pp |
| Q2 2022 | 2022-06-30 | −31.41% | — |
| Q1 2022 | 2022-03-31 | −23.80% | — |
| Q4 2021 | 2021-12-31 | −15.51% | — |
| Q3 2021 | 2021-09-30 | −70.31% | — |
Unicycive Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Unicycive Therapeutics's return on equity increased from −145.04% to −141.14%, a change of +3.89 percentage points. The latest reported quarter, Q2 2026, shows −3.79%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Unicycive Therapeutics source filings ↗